TELA Bio Q3 2026 net loss widens 8% to $9.3 million; revenue falls 8% to $19 million
TELA•TELA Bio's third-quarter 2026 net loss widened 8% year over year to $9.3 million, while revenue fell 8% to $19 million.
1. Quarterly results
TELA Bio's third-quarter 2026 revenue fell 8% year over year to $19 million, primarily due to lower OviTex PRS volumes, partially offset by international growth. Net loss widened 8% to $9.3 million. A strategic cost-reduction initiative targets $17 million in annual operating expense savings to extend cash runway into 2028.
